Red Vascular Technologies

Executive Summary

Red Vascular Technologies is a privately held medical device company headquartered in San Antonio, Texas, focused on addressing the significant clinical challenge of complex aortic aneurysms. These aneurysms involve the take-offs of major arterial branches, making endovascular repair particularly difficult. Red Vascular has developed a patented technology for next-generation branched endografts, aiming to expand the treatable patient population and improve outcomes compared to traditional open surgery or existing endovascular solutions. The company was founded in 2017 and operates in the cardiovascular medical devices space. The market for complex aortic aneurysm repair is sizable and growing, driven by aging populations and increasing adoption of minimally invasive procedures. Red Vascular's differentiated approach targets a high unmet need, potentially offering a safer and more effective option for patients with challenging anatomy. While the company is still in early development stages, its proprietary technology positions it for strategic partnerships or acquisition by larger players in the endovascular space. Success will depend on achieving regulatory milestones and clinical validation. Overall, Red Vascular represents a promising opportunity in a niche but high-value segment of interventional cardiology.

Upcoming Catalysts (preview)

• Q3 2026FDA Breakthrough Device Designation for Branched Endograft60% success
• Q4 2026Initiation of First-in-Human Clinical Study70% success
• Q1 2027Strategic Partnership or Licensing Agreement with Major Cardiovascular Device Company40% success